News Snapshot:
Toronto, Ontario–(Newsfile Corp. – June 20, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“ Clearmind ” or the “ Company “), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that, further to its press release of May 27, 2021, it intends to increase its previously announced private placement from gross proceeds of $6,000,000 to a maximum of up to $6,225,000 (the “ Gross Proceeds “) by way of a non-brokered private placement (the “ Private Placement “). The Private Placement will now consist of...
